Table 1.
Bacterial strains used for the experiments.
| Strain | ST | Year of isolation | Origin of the sample | Inc. groups | Sequencing technique | Antibiotic susceptibility a | Reference |
|---|---|---|---|---|---|---|---|
| Escherichia coli M19736 | 615 | 2015 | Blood culture | IncI2, IncFII, IncI1-I (Alpha) | Illumina MiSeq |
Resistant: AMN, AMC, CMP, CIP, FOS, TET Intermediate: AMS |
Rapoport et al. (2016); Tijet et al. (2017) |
| Escherichia coli SM5 | 131 | 2010 | Urine | IncFIB, IncFII | Illumina MiSeq |
Resistant: AMN, CAZ, CRO, FEP, AZT, TAZ, AMC, AMS, CIP, TMS, FOS Intermediate: AKN |
Sennati et al. (2012) |
| Klebsiella pneumoniae HA7Kp | 18 | 2018 | Rectal swab | IncM1, IncHI1B/IncFIB | Illumina MiSeq |
Resistant: AMN, CAZ, CRO, AZT, MEM, IMI, TAZ, AMC, AMS, TMS Intermediate: FEP, TET |
Knecht et al. (2022) |
| Klebsiella pneumoniae HA31Kp | 11 | 2018 | Tracheal aspirate | IncFII, Col440I, IncFIB(K) | Illumina MiSeq | Resistant: AKN, GEN, AMN, CAZ, CRO, FEP, AZT, MEM, IMI, TAZ, AMC, AMS, CMP, CIP, TMS, FOS | Álvarez et al. (2024) |
| Serratia marcescens SM938 | NA | 2018 | Blood culture | IncC | Illumina MiSeq/MinION |
Resistant: AMN, CAZ, CRO, TAZ, AMC, AMS, MEM, IMI Intermediate: FEP, AZT |
This study |
| Escherichia coli TOP 10::paadB | 10 | NA | Laboratory | p15A | Illumina MiSeq | Resistant: GEN, CMP | Quiroga (2012) |
| Escherichia coli J53 | 10 | NA | Laboratory model | NA | Illumina NextSeq 500/MinION | Resistant: AZI | Matsumura et al. (2018) |
General information on the bacterial strains used for the experiments including sequence type (ST), source of isolation, year of isolation, sequencing technique, incompatibility groups (inc. groups), and antibiotic susceptibility.
AKN, amikacin; GEN, gentamicin; AMN, ampicillin; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; AZT, aztreonam; MEM, meropenem; IMI, imipenem; TAZ, piperacillin/tazobactam; AMC, amoxicillin/clavulanic; AMS, ampicillin/sulbactam; CMP, chloramphenicol; CIP, ciprofloxacin; TMS, trimethoprim/sulfamethoxazole; FOS, fosfomycin; TET, tetracycline; AZI, sodium azide; NA, not applicable.
The results were interpreted according to the Clinical and Laboratory Standards Institute guidelines (CLSI, 2023).